Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

96.70 -0.27 (-0.28%)

Streaming Delayed Price Updated: 11:07 AM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

70 71 Next >

Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent Expiry ↗

December 13, 2022

At Pipeline Day, Pfizer Inc (NYSE: PFE) forecasts annual revenue from its mRNA vaccine portfolio could reach $10-$15 billion by 2030.

Via Benzinga

Why Merck's $250 Million Investment In Moderna May Have Just Paid Off ↗

December 13, 2022

Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data.

Via Investor's Business Daily

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

December 09, 2022

From BioNTech SE

Via GlobeNewswire

FDA Authorizes Pfizer/BioNTech And Moderna's Bivalent COVID Shots For 6 Months Old ↗

December 08, 2022

Via Benzinga

BioNTech, Ryvu Therapeutics Join Forces For Immuno-Modulatory Candidates ↗

November 30, 2022

Via Benzinga

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

December 08, 2022

From Pfizer Inc.

Via Business Wire

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

December 08, 2022

From BioNTech SE

Via GlobeNewswire

US Supports Delay On COVID Patent Waiver Extension Decision ↗

December 06, 2022

Developing countries have been pushing for a patent waiver extension for COVID-19, which many developed countries argue could discourage pharma companies from responding rapidly to future global health...

Via Benzinga

UK's Regulatory Agency Backs Pfizer/BioNTech's COVID-19 Vaccine For Youngest Kids ↗

December 06, 2022

Via Benzinga

Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗

December 06, 2022

Via Benzinga

BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts ↗

December 02, 2022

Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 01, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

November 30, 2022

From BioNTech SE

Via GlobeNewswire

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

November 28, 2022

These two companies are facing short-term issues that are likely to give way to long-term success.

Via The Motley Fool

Is Novavax Stock a Buy Now? ↗

November 26, 2022

There's probably not much good news coming for this biotech in the near future.

Via The Motley Fool

European Official Says COVID-19 Booster Uptake Disappointing In The Region ↗

November 25, 2022

Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...

Via Benzinga

Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains ↗

November 25, 2022

Researchers are working on an experimental pan-influenza vaccine based on the famed mRNA technology to provide broad protection.

Via Benzinga

Is Now the Time for Income Investors to Buy This Big Pharma Stock? ↗

November 24, 2022

This drugmaker is among the most dominant pharmaceutical companies in the world.

Via The Motley Fool

7 Stocks on the Perfect 10 List ↗

November 23, 2022

Companies that have strong quality, value, or growth grades are the stocks to buy once markets recognize their business potential.

Via InvestorPlace

PFE Stock Could Be the Booster Shot Your Portfolio Needs Now ↗

November 23, 2022

PFE stock still remains a dirt-cheap dividend darling, even after across-the-board earnings beats and lifted guidance.

Via InvestorPlace

Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It ↗

November 22, 2022

COVID-19 cases have spiked again in China, sparking fresh lockdown measures in the nation's capital. Jim Cramer has suggested that Chinese President Xi Jinping isn't telling the whole story.

Via Benzinga

2 Reasons to Buy Pfizer and 1 Reason to Sell ↗

November 20, 2022

The pharmaceutical company is looking for a future beyond COVID-19 therapies.

Via The Motley Fool

After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade ↗

November 18, 2022

Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust.

Via Benzinga

7 Stocks to Sell Right Now… and 1 to Buy ↗

November 18, 2022

Although red ink can sometimes bring an opportunity for contrarianism, these (except one) market ideas represent stocks to sell.

Via InvestorPlace

Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages ↗

November 18, 2022

Via Benzinga

Market Rally Holds Key Levels, But Breakouts Struggle; Walmart, Target, Nvidia In Focus: Weekly Review ↗

November 18, 2022

Walmart, Target and Nvidia were key earnings movers.

Via Investor's Business Daily

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

November 18, 2022

From BioNTech SE

Via GlobeNewswire

Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is The Demand There? ↗

November 17, 2022

The biggest question facing the shot is whether there will be demand for it.

Via Investor's Business Daily

Ukraine Asserts It Does Not Take Blame For Poland Missile Attack, Crypto Exchange Gemini Suffers $485M In Outflows, FTX, Bahamas Regulator Lock Horns Over Control Of Bankruptcy Proceedings: Top Stories Thursday, Nov. 17 ↗

November 17, 2022

CNBC

Via Benzinga

Pfizer, BioNTech Start Work On Next-Gen COVID-19 Vaccine Candidate For Broader Protection ↗

November 17, 2022

Via Benzinga

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

70 71 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.